220 related articles for article (PubMed ID: 12038948)
1. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
Fife RS; Chase WF; Dore RK; Wiesenhutter CW; Lockhart PB; Tindall E; Suen JY
Arch Intern Med; 2002 Jun; 162(11):1293-300. PubMed ID: 12038948
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.
Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS
Clin Rheumatol; 2008 Apr; 27(4):429-36. PubMed ID: 17899308
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome].
Ogawa N; Shimoyama K; Karasawa H; Fukushima T; Masaki Y; Wano Y; Hirose Y; Sugai S
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Oct; 27(5):330-7. PubMed ID: 15559322
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
[TBL] [Abstract][Full Text] [Related]
6. Effect of cevimeline on salivary components in patients with Sjögren syndrome.
Suzuki K; Matsumoto M; Nakashima M; Takada K; Nakanishi T; Okada M; Ohsuzu F
Pharmacology; 2005 May; 74(2):100-5. PubMed ID: 15722648
[TBL] [Abstract][Full Text] [Related]
7. Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.
Komai K; Shiozawa K; Tanaka Y; Yoshihara R; Tanaka C; Sakai H; Yamane T; Murata M; Tsumiyama K; Hashiramoto A; Shiozawa S
Mod Rheumatol; 2009; 19(4):416-9. PubMed ID: 19452244
[TBL] [Abstract][Full Text] [Related]
8. Efficacy prediction of cevimeline in patients with Sjögren's syndrome.
Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I
Clin Rheumatol; 2007 Aug; 26(8):1320-7. PubMed ID: 17221146
[TBL] [Abstract][Full Text] [Related]
9. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer.
Chambers MS; Posner M; Jones CU; Biel MA; Hodge KM; Vitti R; Armstrong I; Yen C; Weber RS
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1102-9. PubMed ID: 17379432
[TBL] [Abstract][Full Text] [Related]
10. [The effectiveness of cevimeline hydrochloride on dry cough in Sjögren's syndrome].
Nishinarita M; Hanzawa M; Iikuni N; Ota S
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Apr; 27(2):99-102. PubMed ID: 15164930
[TBL] [Abstract][Full Text] [Related]
11. Cevimeline.
Weber J; Keating GM
Drugs; 2008; 68(12):1691-8. PubMed ID: 18681491
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome.
Noaiseh G; Baker JF; Vivino FB
Clin Exp Rheumatol; 2014; 32(4):575-7. PubMed ID: 25065774
[TBL] [Abstract][Full Text] [Related]
13. Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial.
Cifuentes M; Del Barrio-Díaz P; Vera-Kellet C
Br J Dermatol; 2018 Nov; 179(5):1056-1061. PubMed ID: 29432648
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.
Witsell DL; Stinnett S; Chambers MS
Head Neck; 2012 Aug; 34(8):1136-42. PubMed ID: 22231734
[TBL] [Abstract][Full Text] [Related]
15. [Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia].
Shiozawa A
Nihon Yakurigaku Zasshi; 2002 Oct; 120(4):253-8. PubMed ID: 12425151
[TBL] [Abstract][Full Text] [Related]
16. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
[TBL] [Abstract][Full Text] [Related]
17. Effect of cevimeline on radiation-induced salivary gland dysfunction and AQP5 in submandibular gland in mice.
Takakura K; Takaki S; Takeda I; Hanaue N; Kizu Y; Tonogi M; Yamane GY
Bull Tokyo Dent Coll; 2007 May; 48(2):47-56. PubMed ID: 17978545
[TBL] [Abstract][Full Text] [Related]
18. Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia.
Chambers MS; Jones CU; Biel MA; Weber RS; Hodge KM; Chen Y; Holland JM; Ship JA; Vitti R; Armstrong I; Garden AS; Haddad R
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1369-76. PubMed ID: 17855005
[TBL] [Abstract][Full Text] [Related]
19. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
Fox RI
Adv Exp Med Biol; 2002; 506(Pt B):1107-16. PubMed ID: 12614037
[No Abstract] [Full Text] [Related]
20. A new medication for treatment of dry mouth in Sjögren's syndrome.
al-Hashimi I; Taylor SE
Tex Dent J; 2001 Apr; 118(3):262-6. PubMed ID: 11404944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
